Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer

Abstract

Background Non‐small cell lung cancer (NSCLC) is one of the most common human malignancies and the leading cause of cancer‐related death. Over the past few decades, genomic alterations of cancer driver genes have been identified in NSCLC, and molecular testing and targeted therapies have become standard care for lung cancer patients. Here we studied the unique genomic profile of driver genes in Chinese patients with NSCLC by next‐generation sequencing (NGS) assay. Materials and Methods A total of 1,200 Chinese patients with NSCLC were enrolled in this study. The median age was 60 years (range: 26–89), and 83% cases were adenocarcinoma. NGS‐based genomic profiling of major lung cancer‐related genes was performed on formalin‐fixed paraffin‐embedded tumor samples and matched blood. Results Approximately 73.9% of patients with NSCLC harbored at least one actionable alteration recommended by the National Comprehensive Cancer Network guideline, including epidermal growth factor receptor (EGFR), ALK, ERBB2, MET, BRAF, RET, and ROS1. Twenty‐seven patients (2.2%) harbored inherited germline mutations of cancer susceptibility genes. The frequencies of EGFR genomic alterations (both mutations and amplification) and ALK rearrangement were identified as 50.1% and 7.8% in Chinese NSCLC populations, respectively, and significantly higher than the Western population. Fifty‐six distinct uncommon EGFR mutations other than L858R, exon19del, exon20ins, or T790M were identified in 18.9% of patients with EGFR‐mutant NSCLC. About 7.4% of patients harbored both sensitizing and uncommon mutations, and 11.6% of patients harbored only uncommon EGFR mutations. The uncommon EGFR mutations more frequently combined with the genomic alterations of ALK, CDKN2A, NTRK3, TSC2, and KRAS. In patients <40 years of age, the ALK‐positive percentage was up to 28.2%. Moreover, 3.2% of ALK‐positive patients harbored multi ALK rearrangements, and seven new partner genes were identified. Conclusion More unique features of cancer driver genes in Chinese NSCLC were identified by next‐generation sequencing. These findings highlighted that NGS technology is more feasible and necessary than other molecular testing methods, and suggested that the special strategies are needed for drug development and targeted therapy for Chinese patients with NSCLC. Implications for Practice Molecular targeted therapy is now the standard first‐line treatment for patients with advanced non‐small cell lung cancer (NSCLC). Samples of 1,200 Chinese patients with NSCLC were analyzed through next‐generation sequencing to characterize the unique feature of uncommon EGFR mutations and ALK fusion. The results showed that 7.4% of EGFR‐mutant patients harbored both sensitizing and uncommon mutations and 11.6% harbored only uncommon mutations. Uncommon EGFR mutations more frequently combined with the genomic alterations of ALK, CDKN2A, NTRK3, TSC2, and KRAS. ALK fusion was more common in younger patients, and the frequency decreased monotonically with age. 3.2% of ALK‐positive patien...

Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms*

“…RET fusions are among the many RTK fusions described in human neoplasia. RET rearrangements have been well described in epithelial neoplasms including lung, thyroid, breast, and colorectal cancers and salivary gland tumours 9–17 . RET ‐rearranged mesenchymal neoplasms are an emerging group, with only single case reports and small series published under a variety of nosological terms (Table 1).…”

Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC

“…For example, exon 20 insertion [14] and de novo T790M [15] are resistant to early generation EGFR-TKIs. However, other "common" uncommon EGFR mutations include G719X (2-6 % of all EGFR mutations), L861Q (1.3-3.2 %) and S768I (1.3-3 %) [16][17][18][19][20] have been demonstrated sensitive to EGFR-TKIs [18,21,22]. Among them, second-generation EGFR-TKI afatinib showed a median PFS as 10.7 months [23] and has been approved by Food and Drug Administration (FDA) for patients harboring G719X/L861Q/S768I in 2018.…”

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation

“…Clinical data suggest that patients harboring tumors without sensitizing EGFR mutations should not be treated with EGFR-TKIs in any line of therapy. These sensitizing EGFR mutations are found in approximately 20% of white patients with NSCLC and up to 45.8% of Chinese patients [7,8].…”